• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

One year experience with erenumab: real-life data in 30 consecutive patients.

作者信息

Ranieri Angelo, Alfieri Gennaro, Napolitano Massimo, Servillo Giovanna, Candelaresi Paolo, Di Iorio Walter, Longo Katia, Maniscalco Giorgia Teresa, Renna Rosaria, Rippa Mariana, Salvatore Simona, Sagnelli Anna, Florio Ciro, Manzo Valentino

机构信息

Department of Neurology and Stroke Unit - AORN "A. Cardarelli", Via A. Cardarelli 9, 80131, Naples, Italy.

Headache Centre - Department of Neurology and Stroke Unit - AORN "A. Cardarelli", Via A. Cardarelli 9, 80131, Naples, Italy.

出版信息

Neurol Sci. 2020 Dec;41(Suppl 2):505-506. doi: 10.1007/s10072-020-04677-y.

DOI:10.1007/s10072-020-04677-y
PMID:32845486
Abstract
摘要

相似文献

1
One year experience with erenumab: real-life data in 30 consecutive patients.依瑞奈尤单抗的一年使用经验：30例连续患者的真实数据。
Neurol Sci. 2020 Dec;41(Suppl 2):505-506. doi: 10.1007/s10072-020-04677-y.
2
Erenumab: from scientific evidence to clinical practice-the first Italian real-life data.依瑞奈尤单抗：从科学证据到临床实践——意大利的首批真实世界数据
Neurol Sci. 2019 May;40(Suppl 1):177-179. doi: 10.1007/s10072-019-03839-x.
3
Erenumab efficacy in highly resistant chronic migraine: a real-life study.erenumab在高度耐药性慢性偏头痛中的疗效：一项真实世界研究。
Neurol Sci. 2020 Dec;41(Suppl 2):457-459. doi: 10.1007/s10072-020-04658-1.
4
Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.依瑞奈umab（AMG 334），一种针对经典 CGRP 受体的单克隆拮抗剂抗体，不会损害人类孤立颅动脉对其他血管活性物质的舒张或收缩反应。
Cephalalgia. 2019 Dec;39(14):1745-1752. doi: 10.1177/0333102419867282. Epub 2019 Jul 31.
5
Erenumab: First Global Approval.依瑞奈尤单抗：全球首次获批。
Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.
6
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center.依瑞奈尤单抗治疗159例高频慢性偏头痛患者：来自博洛尼亚头痛中心的真实结果
Neurol Sci. 2020 Dec;41(Suppl 2):483-484. doi: 10.1007/s10072-020-04667-0.
7
Efficacy of erenumab 70 mg in chronic migraine: Vicenza experience.70毫克erenumab治疗慢性偏头痛的疗效：维琴察经验
Neurol Sci. 2020 Dec;41(Suppl 2):479-480. doi: 10.1007/s10072-020-04665-2.
8
Erenumab (Aimovig) for Migraine Prophylaxis in Adults.erenumab（Aimovig）用于成人偏头痛的预防。
Am Fam Physician. 2019 Jun 15;99(12):781-782.
9
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.欧洲头痛联合会关于使用作用于降钙素基因相关肽或其受体的单克隆抗体预防偏头痛的指南。
J Headache Pain. 2019 Jan 16;20(1):6. doi: 10.1186/s10194-018-0955-y.
10
A longitudinal clinical and MRI evaluation of the treatment with erenumab.依瑞奈尤单抗治疗的纵向临床及磁共振成像评估
Neurol Sci. 2020 Dec;41(Suppl 2):463-464. doi: 10.1007/s10072-020-04660-7.

引用本文的文献

1
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review.关于偏头痛 CGRP 通路单克隆抗体的真实世界证据研究的方法学考虑：系统评价。
J Headache Pain. 2023 Jun 22;24(1):75. doi: 10.1186/s10194-023-01611-3.
2
Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment.erenumab及降钙素基因相关肽对慢性偏头痛昼夜节律类型的可能影响：一项为期12个月治疗的真实病例研究
J Clin Med. 2023 May 21;12(10):3585. doi: 10.3390/jcm12103585.
3
Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.
减轻偏头痛负担：CGRP通路靶向预防性治疗的安全性和有效性
J Clin Med. 2022 Jul 27;11(15):4359. doi: 10.3390/jcm11154359.
4
Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence.依瑞奈玛单抗治疗慢性偏头痛：来自英国一所三级医疗中心的经验及其与其他真实世界证据的比较。
Eur J Neurol. 2022 Aug;29(8):2473-2480. doi: 10.1111/ene.15364. Epub 2022 May 9.
5
Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.erenumab预防偏头痛：聚焦患者选择、观点与结果。
Ther Clin Risk Manag. 2022 Apr 5;18:359-378. doi: 10.2147/TCRM.S263825. eCollection 2022.
6
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.依瑞奈尤单抗的相对和绝对疗效比较：50%的应答率足够吗？来自 ESTEEMen 研究的结果。
J Headache Pain. 2022 Mar 19;23(1):38. doi: 10.1186/s10194-022-01408-w.
7
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.基于 MIDAS 评分的三种抗 CGRP 单克隆抗体在难治性慢性偏头痛患者中的长期疗效。
CNS Drugs. 2022 Feb;36(2):191-202. doi: 10.1007/s40263-021-00893-y. Epub 2022 Feb 11.
8
Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey.依瑞奈尤单抗治疗偏头痛的患者报告结局：一项全国性患者调查结果
Neurol Sci. 2022 May;43(5):3305-3312. doi: 10.1007/s10072-021-05861-4. Epub 2022 Jan 10.
9
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.艾瑞司umab治疗3个月结局的性别差异——男性使用艾瑞司umab治疗的疗效和安全性研究
Front Neurol. 2021 Dec 16;12:774341. doi: 10.3389/fneur.2021.774341. eCollection 2021.
10
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.偏头痛预防中单克隆抗体依瑞奈umab 的真实世界证据数据：德国治疗医生的观点。
J Headache Pain. 2021 Nov 6;22(1):133. doi: 10.1186/s10194-021-01344-1.